Australia’s AOD landscape: Reflections on 15 years serving on the Board of a national research institute

June 2024
This edition's opinion piece is written by retiring NDRI Board Chair Adjunct Professor Michael Moore, who reflects on Australia's AOD landscape and informing and influencing policy makers.
Read more
March 2024

Cannabis use disorders: an unappreciated risk of medical use for chronic conditions?

Ms Danielle Dawson from the National Centre for Youth Substance Use Research (NCYSUR) examines recent changes in Australian medicinal cannabis policy
November 2023

Drug detection dogs: An ineffective and inequitable policing strategy that needs to stop

Authors: Ms Daisy Gibbs, Evaluation Officer, Burnet Institute A/Prof Caitlin Hughes, Associate Professor in Criminology and Drug Policy, Centre for
September 2023

Take-home naloxone: research dispels concern that it increases drug-related risk behaviour

Dr Samantha Colledge-Frisby examines the perception that people may engage in risk compensation when they have naloxone at hand.
June 2023

What are my tertiary alcohol and other drug qualification options?

The last scoping of tertiary level Australian alcohol and other drug (AOD) qualifications was undertaken two decades ago.
April 2023

Minimum unit pricing in the Northern Territory. What we know, and where to next

National Drug Research Institute
February 2023

Encounters with police drug detection dogs at music festivals among people who regularly use ecstasy and/or other illicit stimulants

Despite growing evidence challenging the effectiveness and legality of drug dog operations, and recommendations to cease operations at music festivals
November 2022

Facilitating First Nations Australians’ self-determination policy making processes

National Drug Research Institute
September 2022

Feasibility, consumer acceptability, and behavioural outcomes associated with take-home fentanyl test strips

July 2022

Opioid Agonist Therapy in Australia: A History

A new NCETA publication aims to document the substantial contribution that opioid agonist therapy (OAT) has made to public health and to the life of i
May 2022

Our systems undervalue prevention – FASD is a case in point

Australia spends less than 2% per annum of its health budget on prevention.

Pages